UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038255
Receipt number R000043610
Scientific Title Influence on reducing allergies reactions of eyes and nose by consumption of test foods
Date of disclosure of the study information 2020/10/18
Last modified on 2020/10/19 09:33:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Influence on reducing allergies reactions of eyes and nose by consumption of test foods

Acronym

Influence on reducing allergies reactions of eyes and nose by consumption of test foods

Scientific Title

Influence on reducing allergies reactions of eyes and nose by consumption of test foods

Scientific Title:Acronym

Influence on reducing allergies reactions of eyes and nose by consumption of test foods

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm the influence on reducing allergies reactions of eyes and nose by 8 weeks consumption of test food

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Nasal symptom score of JRQLQ

Key secondary outcomes

* Nasal symptom score for severity classification of allergies
* Nasal examination
* Ocular symptoms score
* QOL score
* Concentration of serum non-specific IgE
* Concentration of serum specific IgE against CAP16
* White blood cell image
* Nasal discharge neutrophils
* Medication Score
* Incidence of adverse events and side effects


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake two packs of test food a day for eight weeks.

Interventions/Control_2

Intake two packs of control food a day for eight weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Males and females aged 20 to 64 when informed consent, who match the inclusion criteria (2) and (4) or (3) and (4) as be shown below.
2) Healthy subjects who have, include used to have, nose allergy. And healthy subjects who don't and/or won't use allergy treatment medicines, before the test and/or during the test period.
3) Light symptom subjects who have, include used to have, nose allergy. And those subjects who will use allergy treatment medicines sometimes (not regularly), before the test and/or during the test period.
4) Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.

Key exclusion criteria

1) Subjects who plan some treatment during test period.
2) Subjects who use oral steroid medicine in order to treatment allergy.
3) Subjects who regularly use and/or are not able to quit use medicines, quasi-drugs and herbal medicines those have the inhibition effects of allergy and concerned to give influence for test results.
4) Subjects who regularly use and/or are not able to quit use healthy foods those advocate to have the inhibition effects of allergy and concerned to give influence for test results.
5) Females who are pregnant or could become pregnant, and who are lactating.
6) Subjects who have previous and/or current medical history of serious disease
7) Subjects who use oral medicines and/or nasal drops those are antihistamine or anti-allergy
8) Subjects who don't intake test food and/or don't enter the Web diary against the instruction of administrator during test period.
9) Subjects who excessive alcohol intake.
10) Subjects who have non-allergic nasal inflammation
11) Subjects who can't eat lotus root
12) Subjects who have food allergy
13) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests.
14) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study.
15) Males who donated over 400mL blood within the last three months to the current study.
16) Females who donated over 400mL blood within the last four months to the current study.
17) Males who will be collected over 1200mL blood, when the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study.
18) Females who will be collected over 800mL blood when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study.
19) Others who have been determined ineligible by principal investigator or sub-investigator.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Kenichi
Middle name
Last name Nagamine

Organization

NICHIREI BIOSCIENCES INC.

Division name

Global Innovation Center

Zip code

350-1331

Address

1-11-8, Shin Sayama, Sayama-shi, Saitama, 350-1331, Japan

TEL

04-2930-2108

Email

nagaminek@nichirei.co.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Ichinohe

Organization

CPCC Company Limited

Division name

Planning & Sales Department

Zip code

101-0047

Address

4F Sanwauchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

NICHIREI BIOSCIENCES INC.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwauchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 10 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 08 Month 19 Day

Date of IRB

2019 Year 08 Month 16 Day

Anticipated trial start date

2019 Year 10 Month 18 Day

Last follow-up date

2019 Year 12 Month 13 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 10 Month 09 Day

Last modified on

2020 Year 10 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043610


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name